Benign Prostatic Hyperplasia

Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural checklists and pre-morcellation hemostasis remain the most critical safety practices for avoiding morcellator injury.

The first patients have been treated in WOLVERINE, a prospective feasibility trial of the Edison Histotripsy System for BPH.

Clearance of the non-permanent implant technology is backed by safety and efficacy results from the pivotal Expander-2 trial.

At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.

The results from this study are expected to support an application to the FDA for premarket approval of the Butterfly device.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

Dean Elterman, MD, MSc, FRCSC, attributes the 99% catheter-free discharge rate in the BREEZE study largely to appropriate patient selection.

Steven A. Kaplan, MD, frames the greatest value of ProVee not as competition with other procedures, but as a compelling alternative to chronic medical therapy.

Steven A. Kaplan, MD, emphasizes that ProVee is well suited for office-based or ambulatory settings and is designed to be performed under local anesthesia

Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

Dean Elterman, MD, MSc, FRCSC, emphasizes that a key differentiator of this new class of devices lies in material science and mechanism of action.

Mechanistically, Kaplan emphasizes that ProVee’s key differentiator is not simply that it is an expanding urethral device, but that it belongs to a new class of flexible, catheter-like technologies.

Data from the pivotal BREEZE study indicated a mean IPSS improvement of 37% in patients receiving the system.

The approval is supported by results from the randomized ProVIDE study.

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication

We recap notable headlines from last month in the benign urology space.

Martin B. Richman, MD, MBA, FACS, outlines recent advancements in BPH, with an emphasis on the importance of a patient-focused approach to care.

According to the authors, these findings suggest that FloStent could serve as an effective interim solution for men who are awaiting TURP.

Kanika Searvance, MD, and Yasin Bhanji, MD, discuss the evolution of BPH care.

Experts discuss the ways in which AI could transform patient care and improve physician workflows, particularly for benign prostatic hyperplasia.

Jennifer A. Robles, MD, MPH, discusses the future for HoLEP in terms of innovation and wider integration into urologic practice.

The presentations featured data on the drug candidate BOTRESO for BPH and LUTS, as well as on the prostate cancer prevention drug MCS-8.

"We are lucky to be in the position to offer so many treatment options customized to address [patients'] needs and help them enjoy life," says Kevin C. Zorn, MD, FRCSC, FACS.